RARA and acute myeloid leukemia: Multiple studies have demonstrated a central role for dysregulated epigenetics in AML (The Cancer Genome Atlas Research Network, 2013; Conway O'Brien et al., 2014) and we have previously demonstrated aberrant histone modifications in AML patient samples on chromatin localized to the RARA gene (Glasow et al., 2008), which encodes retinoic acid receptor alpha (RARα, NR1B1), a key driver of myeloid differentiation in response to binding of its ligand ATRA (Collins, 2002).